Thyroid Eye Disease Treatment

Treating Thyroid Eye Disease

There is no single treatment for thyroid eye disease — the right plan depends on two things: the phase of the disease (active and inflamed vs. stable and burned-out) and its severity. Mild disease is managed conservatively; moderate-to-severe active disease calls for medical therapy such as Tepezza; and sight-threatening disease is an emergency. Identifying where a patient falls on this spectrum is what determines treatment.

Treatment Varies by Severity

• Mild TED: Supportive measures — ocular-surface (dry-eye) care, smoking cessation, and selenium supplementation. Most mild cases stabilize without aggressive treatment.
• Moderate-to-severe, active TED: Anti-inflammatory and targeted medical therapy — Tepezza® (teprotumumab), intravenous corticosteroids, and in selected cases orbital radiotherapy — to reduce proptosis, inflammation, and double vision during the active phase.
• Sight-threatening TED: Dysthyroid optic neuropathy or severe corneal exposure is an emergency, treated with high-dose IV steroids and urgent orbital decompression to save vision.

Ocular Surface & Dry-Eye Symptoms

Almost every patient with thyroid eye disease has some degree of ocular-surface irritation — from a combination of lid retraction, proptosis, incomplete blinking, and inflammation that leaves the cornea exposed. Managing these symptoms is the foundation of care at every severity:

• Lubrication: preservative-free artificial tears through the day and a thicker lubricating ointment at night.
• Nighttime protection: taping the lids closed or using a moisture-chamber/eye shield when the lids do not fully close (lagophthalmos).
• Reducing tear loss: punctal plugs in selected patients to keep the surface moist.
• Treating exposure: prompt attention to any corneal breakdown, which can threaten the eye if neglected.

Active-Phase Medical Therapy & Tepezza

During active inflammation, medical therapy aims to calm the disease and shrink the swollen orbital tissues. Tepezza® (teprotumumab) is an IGF-1R inhibitor infusion and the first drug FDA-approved specifically for thyroid eye disease — it directly reduces proptosis, double vision, and inflammation. Corticosteroids (often intravenous) and, in selected cases, orbital radiotherapy are also used.

Rehabilitative Surgery (Stable Phase)

Once the disease has been stable for roughly six months, surgery corrects the changes the active phase left behind. It is performed in a specific order, because each step can change what the next must correct:

1. Orbital decompression — enlarges the bony orbit to set a bulging eye back and relieve optic-nerve compression.
2. Strabismus surgery — realigns the eyes to eliminate double vision.
3. Eyelid surgery — lowers retracted lids and restores a natural, protective lid position.

The single most important thing a patient can do at every stage is to stop smoking — it is the strongest modifiable risk factor for severe disease and a poorer response to treatment.